Pneumococcal Vaccines

Next-Generation Protection Against Pneumococcal Disease

Pneumococcal Vaccines

Pneumococcal infections, caused by Streptococcus pneumoniae, are a leading cause of pneumonia, meningitis, and sepsis, particularly in children, older adults, and immunocompromised individuals. Despite the success of current pneumococcal vaccines, challenges remain, including serotype limitations and high production costs.

At Abera Bioscience, we are developing an innovative nasal pneumococcal vaccine using our proprietary BERA platform, designed to provide broader, more effective protection by inducing strong mucosal and systemic immunity.

The Need for Next-Generation Pneumococcal Vaccines

Current pneumococcal conjugate vaccines (PCVs) have significantly reduced disease burden, but they have limitations:

  • Serotype Dependence – Protection is limited to specific serotypes, while emerging strains pose new threats.
  • High Costs & Accessibility Issues – PCVs are expensive and difficult to distribute globally.
  • Lack of Mucosal Immunity – Traditional vaccines do not prevent Streptococcus pneumoniae colonization in the nasal passages, allowing continued transmission.

 

To address these challenges, Abera Bioscience is developing a nasal pneumococcal vaccine designed to:

  • Block colonization at the entry point – Preventing bacterial spread and transmission.
  • Induce long-lasting immunity – Offering durable, broad protection.
  • Enhance accessibility – Using a cost-effective and scalable production method.

Abera Bioscience’s Pneumococcal Vaccine Approach

Leveraging our BERA technology, we are pioneering a novel pneumococcal vaccine candidate that is:

  • Mucosal-Targeted – Administered nasally to trigger immune responses where infections begin.
  • Broadly Protective – Targeting conserved pneumococcal antigens for serotype-independent immunity.
  • Innovative & Scalable – Utilizing a modular design for rapid adaptability and efficient manufacturing.

 

Unlike traditional vaccines that only provide systemic immunity, our nasal pneumococcal vaccine aims to prevent infection before it starts, reducing transmission and severe disease progression.

Pneumococcal Vaccines & Pandemic Preparedness

Emerging pneumococcal strains and the risk of antibiotic resistance make vaccine innovation critical. Our mucosal vaccine approach not only enhances pneumococcal disease prevention but also strengthens global pandemic preparedness by:

  • Reducing bacterial transmission through mucosal immunity.
  • Providing cross-protection against multiple pneumococcal strains.
  • Offering a scalable vaccine solution for global immunization efforts.

Join Us in Advancing Pneumococcal Vaccine Innovation

Abera Bioscience is committed to developing next-generation pneumococcal vaccines that redefine disease prevention. We are actively engaging with research institutions, healthcare organizations, and industry partners to drive innovation in mucosal vaccines.

You can learn more about nasal Pneumococcal vaccines here. 

Contact us to learn more about our research and collaboration opportunities.